This pilot study, sponsored by the University of California, Davis, aims to evaluate a novel imaging technique that combines PET and dual-energy CT to enhance the assessment of bone marrow composition in multiple myeloma patients undergoing CAR T-cell therapy. The potential commercial implications are significant, as advancements in imaging technologies can lead to improved diagnostic capabilities and treatment monitoring in oncology. The study's findings may position UC Davis as a leader in innovative imaging methodologies, attracting partnerships with pharmaceutical companies and imaging device manufacturers. Given the increasing prevalence of multiple myeloma and the growing market for CAR T-cell therapies, successful validation of this imaging method could open avenues for further research funding and commercialization opportunities in the oncology imaging sector.